Anaplastic Large Cell Lymphoma — Clinical Trials

MONDO:002032538 active·18 recruitingLast updated: Mar 16, 2026, 10:45 AM

Trial Landscape

Anaplastic Large Cell Lymphoma has an active clinical trial landscape, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment24

Biological Therapy11

Procedure7

Medical Device2

Gene Therapy1

12 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

Phase 4

9 trials are observational or have no phase designation.

Sponsor Types

Academic/Other29Industry4NIH3Collaborative Network2

Top Sponsors

Corvus Pharmaceuticals, Inc.

Pfizer

Tessa Therapeutics

Turning Point Therapeutics, Inc.

Trial Locations

United States26 trials

China4 trials

France4 trials

Italy3 trials

United Kingdom3 trials

Australia2 trials

Canada2 trials

Denmark2 trials

Taiwan2 trials

Netherlands1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

38 Trials

Phase 3Recruiting

NCT06561048

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Sponsor:Corvus Pharmaceuticals, Inc.

United StatesStarted: Oct 2024Est. completion: Jul 2028Updated: Apr 2025

Phase 3Recruiting

NCT04881838

CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL

Sponsor:Children's Cancer Group, China

ChinaStarted: Mar 2021Est. completion: Mar 2029Updated: Feb 2025

Phase 2Recruiting

NCT04195633

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Sponsor:Fred Hutchinson Cancer Center

United StatesStarted: Jan 2021Est. completion: Mar 2029Updated: Feb 2026

Phase 2Recruiting

NCT05770037

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Sponsor:Cancer Research UK

United KingdomStarted: Dec 2023Est. completion: Oct 2029Updated: Nov 2025

Phase 1Recruiting

NCT07055477

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2025Est. completion: Jun 2044Updated: Feb 2026

Phase 1Recruiting

NCT04925609

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Sponsor:Princess Maxima Center for Pediatric Oncology

FranceStarted: Aug 2022Est. completion: Dec 2033Updated: Dec 2025

Phase 1Recruiting

NCT04094610

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Sponsor:Turning Point Therapeutics, Inc.

United StatesStarted: Mar 2020Est. completion: Sep 2027Updated: Nov 2025

Phase 1Recruiting

NCT06176690

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Sponsor:Baylor College of Medicine

United StatesStarted: Oct 2025Est. completion: Jun 2043Updated: Nov 2025

Phase 1Recruiting

NCT03017820

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Sponsor:Mayo Clinic

United StatesStarted: Apr 2017Est. completion: Apr 2032Updated: Oct 2025

Phase 1Recruiting

NCT06508463

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Sponsor:Mayo Clinic

United StatesStarted: Jan 2024Est. completion: Apr 2032Updated: Oct 2025

Phase 2Active, Not Recruiting

NCT02978625

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2017Est. completion: Sep 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03113500

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Sponsor:City of Hope Medical Center

United StatesStarted: May 2017Est. completion: Jul 2026Updated: Nov 2025

Phase 2Active, Not Recruiting

NCT07013565

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Sponsor:New York Medical College

United StatesStarted: Aug 2025Est. completion: Jul 2030Updated: Oct 2025

Phase 2Active, Not Recruiting

NCT00544115

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Sponsor:City of Hope Medical Center

Started: Oct 2001Est. completion: Apr 2026Updated: Jun 2025

Phase 2Active, Not Recruiting

NCT03703050

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Sponsor:Gustave Roussy, Cancer Campus, Grand Paris

DenmarkStarted: Jan 2019Est. completion: Sep 2025Updated: Nov 2024

Phase 2Active, Not Recruiting

NCT02232516

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Sponsor:Northwestern University

United StatesStarted: Jun 2015Est. completion: Aug 2024Updated: Apr 2024

Last updated over 18 months ago

Phase 1Active, Not Recruiting

NCT03278782

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Nov 2017Est. completion: Jul 2027Updated: Jan 2026

Phase 1Active, Not Recruiting

NCT03602157

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Sponsor:UNC Lineberger Comprehensive Cancer Center

United StatesStarted: Dec 2018Est. completion: Nov 2039Updated: Jan 2026

Phase 1Active, Not Recruiting

NCT02223208

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Sponsor:Fondazione Italiana Linfomi - ETS

ItalyStarted: Sep 2014Est. completion: Feb 2026Updated: Dec 2025

Phase 1Active, Not Recruiting

NCT03598998

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Sponsor:City of Hope Medical Center

United StatesStarted: Feb 2019Est. completion: Feb 2026Updated: Jun 2025

Stay informed about clinical trials for Anaplastic Large Cell Lymphoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 10:45 AM

Anaplastic Large Cell Lymphoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

38 Trials

Open Trials23

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Active Trials15

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas